IN VITRO DIAGNOSTICS Financings Biocept Inc. Biocept Inc. (blood-based molecular diagnostics for solid tumors) netted $8.7mm through the sale of 4.3mm common shares at $2.15 (a slight discount) to
Health care providers and product manufacturers are poring over CMS' recently released 2016 payment system rules. Here are a few key takeaways for device companies from the Medicare hospital outpati